ChinaDaily Briefs

Daily Brief China: L’Occitane, COFCO Joycome Foods, Hutchmed China Ltd, ENN Energy and more

In today’s briefing:

  • L’Occitane (973 HK): No, PLP Is Not Getting A Back-End Bump
  • COFCO Joycome (1610 HK): Brewing a Hog Cycle Upturn?
  • Hutchmed China Ltd (13.HK/​​HCM.US) – Time to Reassess Valuation Prospects Despite the Pain Points
  • Morning Views Asia: China Jinmao Holdings, ENN Energy, ENN Natural Gas, MGM China Holdings


L’Occitane (973 HK): No, PLP Is Not Getting A Back-End Bump

By David Blennerhassett

  • In a long-awaited development, L’Occitane (973 HK)  announced during the lunchbreak yesterday, a scrip alternative. Plus Pleasant Lake Partners (PLP) (3.25%) will accept the Offer (either in cash or scrip). 
  • This was positive news. And the market reacted accordingly, up ~1.0% in the afternoon session.
  • One quirk in the doc was the perception those electing the scrip alternative may get a higher % in the unlisted Offeror. A back-end bump for PLP? (Hint: No).

COFCO Joycome (1610 HK): Brewing a Hog Cycle Upturn?

By Osbert Tang, CFA

  • Cofco Joycome (1610 HK) is in a good position to benefit from the hog cycle upturn. China’s anti-dumping investigation into imported pork from the EU may also disrupt supply.
  • Its average hog price has increased by 12.7% YTD and by 1.6% YoY for 5M24. Market hog price further surged by 10.4% in the week of 12-Jun from end-May.
  • Its P/B of 0.78x is inexpensive at 1SD below the 5-year average. Its peers like Muyuan Foodstuff (002714 CH) and Wens Foodstuff Group (300498 CH) are also interesting. 

Hutchmed China Ltd (13.HK/​​HCM.US) – Time to Reassess Valuation Prospects Despite the Pain Points

By Xinyao (Criss) Wang

  • Takeda’s sales team is fully prepared for the launch of fruquintinib in EU. 2024 full-year overseas sales may once again beat the expectations. High growth is expected from 2024 to 2026.
  • Peak sales of fruquintinib + savolitinib + surufatinib that recorded in HUTCHMED’s revenue is expected to be over US$750 million.Without considering other revenue, market value would reach about US$4.5 billion.
  • HUTCHMED’s pipeline lacks blockbuster products and the indications are small. With the rise of PROTAC, small molecule drugs would face challenges, which would test the management’s resilience in the future.

Morning Views Asia: China Jinmao Holdings, ENN Energy, ENN Natural Gas, MGM China Holdings

By Leonard Law, CFA

Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars